Replies to post #3845 on Cytogenix (fka CYGX)

[neo43]

gimble, the 'going concern' language . . .

is typical for a startup company making no money. IMHO, the chances that the company won't survive past the end of the year are virtually nil. As 'proof,' one need only look at the fact that they just moved to nice new digs, which they wouldn't've done if they weren't sure of obtaining the funding to survive. The only question is how much they'll have to pay for that funding.

[thalio]

gimble,

CYGX has seen tough times, and has weathered tough times. These are not tough times for these guys.

They have money in the bank right now, which is a luxury for them.

One deal, just one, with a big pharma, to use CYGX expression vectors to deliver that pharma's therapeutic molecule could fill this company's coffers for a year. There are over 800 patented molecules out there right now that need a way to get into human cells.

One deal.

CEO, CFO, COO, and VP of scientific development are all buying stock.

Dr. Chen just published a paper revealing the company has a molecule that can make the most resistant bacteria unable to replicate.

A big pharma partner on that one application alone would rocket the stock price to a level where a small placement could again fill the coffers.

CYGX is not closing its doors anytime soon. Unless it's to move into another larger office.

All of this IMO, of course. You hear about them selling the furniture, you let me know. ;-)

Th